Koelis, SAS (“Koelis” or the “Company”, a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer interventions, recently announced that the Centers for Medicare & Medicaid ...

Koelis, SAS (“Koelis” or the “Company”, a leader and innovator in MRI-ultrasound fusion guidance for prostate cancer ...

Profound Medical ( ($TSE:PRN) ) has shared an announcement. Profound Medical announced that The Johns Hopkins Hospital has performed its first ...

Accordingly, it is not surprising that a leading institution such as Johns Hopkins Medicine is at the forefront of this trend. John Hopkins University was an early participant in the clinical ...

Men’s Health Thailand by Dr. Niti Navanimitkul For many men, a diagnosis of prostate cancer comes with two major worries: ...

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...

The objective of this study is to evaluate whether prior Holmium laser enucleation of the prostate (HoLEP) affects the diagnostic accuracy of multiparametric prostate MRI (mpMRI) with PI-RADS scoring ...

Purpose: This study evaluates the impact of high-resolution T2-weighted imaging (T2 HR) combined with deep learning image reconstruction (DLR) on image quality, lesion delineation, and extraprostatic ...

Biparametric MRI, which omits dynamic contrast-enhanced sequences, similarly detected clinically significant prostate cancer to multiparametric MRI. Biparametric MRI was also noninferior to ...

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...